Toshiba America Medical Systems has named John Ariatti as vicepresident of marketing to replace Ravi Sharma, who left the Tustin,CA, firm in July (SCAN 8/2/95). Ariatti is a medical imaging veteranwho previously was director of sales and marketing at
Toshiba America Medical Systems has named John Ariatti as vicepresident of marketing to replace Ravi Sharma, who left the Tustin,CA, firm in July (SCAN 8/2/95). Ariatti is a medical imaging veteranwho previously was director of sales and marketing at Otsuka Electronicsand then at Elscint after that company acquired Otsuka last year.
Ariatti rejoins Toshiba after a stint with the vendor beginningin 1989, when he served as director of the CT business unit andlater as director of MRI marketing. He has also worked with PhilipsMedical Systems.
In his new position, Ariatti oversees marketing for Toshiba'sCT, MRI, nuclear medicine, and vascular and general x-ray products,as well as corporate marketing and marketing communications.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.